A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Trial Profile

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Pamrevlumab (Primary) ; Erlotinib; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors FibroGen
  • Most Recent Events

    • 03 Feb 2017 According to a FibroGen media release, results from this study were published in the Journal of Cancer Clinical Trials.
    • 03 Feb 2017 Results published in the FibroGen Media Release
    • 27 Jan 2016 Results published in FibroGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top